サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1098717

ヒト免疫不全ウイルス（HIV）治療薬の世界市場：シェア、規模、動向、産業分析レポート、流通チャネル別（病院薬局、小売薬局、オンライン薬局、その他）、医薬品クラス別、地域別、セグメント別予測（2022年～2030年）

Human Immunodeficiency Virus (HIV) Drugs Market Share, Size, Trends, Industry Analysis Report, By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others); By Drug Class; By Region; Segment Forecast, 2022 - 2030
出版日: | 発行: Polaris Market Research | ページ情報: 英文 111 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
ヒト免疫不全ウイルス（HIV）治療薬の世界市場：シェア、規模、動向、産業分析レポート、流通チャネル別（病院薬局、小売薬局、オンライン薬局、その他）、医薬品クラス別、地域別、セグメント別予測（2022年～2030年）
出版日: 2022年06月01日
発行: Polaris Market Research
ページ情報: 英文 111 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界のヒト免疫不全ウイルス（HIV）治療薬の市場規模は、20230年までに474億8,000万米ドルに達すると予測されています。

当レポートでは、世界のヒト免疫不全ウイルス（HIV）治療薬市場を調査しており、市場の概要、市場規模や予測、動向、成長要因および抑制要因、流通チャネル・医薬品クラス・地域別などの分析、さらに企業プロファイルなどを提供しています。

目次

第1章 イントロダクション

  • レポートの説明
    • 調査の目的
    • 市場範囲
    • 前提条件
  • ステークホルダー

第2章 エグゼクティブサマリー

  • 市場のハイライト

第3章 調査手法

  • 概要
    • データマイニング
  • 情報源
    • 一次情報源
    • 二次情報源

第4章 世界のヒト免疫不全ウイルス（HIV）治療薬市場の洞察

  • ヒト免疫不全ウイルス（HIV）治療薬市場-業界のスナップショット
  • ヒト免疫不全ウイルス（HIV）治療薬市場力学
    • 推進要因と機会
    • 抑制要因と課題
  • ポーターのファイブフォース分析
    • 供給企業の交渉力
    • 新規参入者の脅威
    • 買い手の交渉力
    • 代替の脅威
    • 既存企業間の競争
  • PESTLE分析
  • ヒト免疫不全ウイルス（HIV）治療薬業界の動向
  • バリューチェーン分析
  • COVID-19影響分析

第5章 世界のヒト免疫不全ウイルス（HIV）治療薬市場：医薬品クラス別

  • 主な調査結果
  • イントロダクション
    • 世界のヒト免疫不全ウイルス（HIV）治療薬、医薬品クラス別（2018年～2030年）
  • ヌクレオシド逆転写酵素阻害剤
    • 世界のヒト免疫不全ウイルス（HIV）治療薬市場、ヌクレオシド逆転写酵素阻害剤、地域別（2018年～2030年）
  • マルチクラス併用製品
    • 世界のヒト免疫不全ウイルス（HIV）治療薬市場、マルチクラス併用製品別、地域別（2018年～2030年）
  • プロテアーゼ阻害剤
    • 世界のヒト免疫不全ウイルス（HIV）治療薬市場、プロテアーゼ阻害剤別、地域別（2018年～2030年）
  • HIVインテグラーゼ鎖転移阻害剤
    • 世界のヒト免疫不全ウイルス（HIV）治療薬市場、HIVインテグラーゼ鎖転移阻害剤別、地域別（2018年～2030年）
  • 非ヌクレオシド逆転写酵素阻害剤
    • 世界のヒト免疫不全ウイルス（HIV）治療薬市場、非ヌクレオシド系逆転写酵素阻害剤別、地域別（2018年～2030年）
  • 侵入阻害剤-CCR5共受容体拮抗薬
    • 世界のヒト免疫不全ウイルス（HIV）治療薬市場、侵入阻害剤別-CCR5共受容体拮抗薬別、地域別（2018年～2030年）
  • 融合阻害剤
    • 世界のヒト免疫不全ウイルス（HIV）治療薬市場、融合阻害剤別、地域別（2018年～2030年）
  • その他
    • 世界のヒト免疫不全ウイルス（HIV）治療薬市場、その他、地域別（2018年～2030年）

第6章 世界のヒト免疫不全ウイルス（HIV）治療薬市場：流通チャネル別

  • 主な調査結果
  • イントロダクション
    • 世界のヒト免疫不全ウイルス（HIV）治療薬市場、流通チャネル別（2018年～2030年）
  • 病院薬局
    • 世界のヒト免疫不全ウイルス（HIV）治療薬市場、病院薬局別、地域別（2018年～2030年）
  • 小売薬局
    • 世界のヒト免疫不全ウイルス（HIV）治療薬市場、小売薬局別、地域別（2018年～2030年）
  • オンライン薬局
    • 世界のヒト免疫不全ウイルス（HIV）治療薬市場、オンライン薬局別、地域別（2018年～2030年）
  • その他
    • 世界のヒト免疫不全ウイルス（HIV）治療薬市場、その他、地域別（2018年～2030年）

第7章 世界のヒト免疫不全ウイルス（HIV）治療薬市場：地域別

  • 主な調査結果
  • イントロダクション
    • ヒト免疫不全ウイルス（HIV）治療薬市場の評価、地域別（2018年～2030年）
  • ヒト免疫不全ウイルス（HIV）治療薬市場-北米
    • 北米：ヒト免疫不全ウイルス（HIV）治療薬市場、流通チャネル別（2018年～2030年）
    • 北米：ヒト免疫不全ウイルス（HIV）治療薬市場、医薬品クラス別（2018年～2030年）
    • ヒト免疫不全ウイルス（HIV）治療薬市場-米国
    • ヒト免疫不全ウイルス（HIV）治療薬市場-カナダ
  • ヒト免疫不全ウイルス（HIV）治療薬市場-欧州
    • 欧州：ヒト免疫不全ウイルス（HIV）治療薬市場、流通チャネル別（2018年～2030年）
    • 欧州：ヒト免疫不全ウイルス（HIV）治療薬市場、医薬品クラス別（2018年～2030年）
    • ヒト免疫不全ウイルス（HIV）治療薬市場-英国
    • ヒト免疫不全ウイルス（HIV）治療薬市場-フランス
    • ヒト免疫不全ウイルス（HIV）治療薬市場-ドイツ
    • ヒト免疫不全ウイルス（HIV）治療薬市場-イタリア
    • ヒト免疫不全ウイルス（HIV）治療薬市場-スペイン
    • ヒト免疫不全ウイルス（HIV）治療薬市場-オランダ
    • ヒト免疫不全ウイルス（HIV）治療薬市場-ロシア
  • ヒト免疫不全ウイルス（HIV）治療薬市場-アジア太平洋
    • アジア太平洋：ヒト免疫不全ウイルス（HIV）治療薬市場、流通チャネル別（2018年～2030年）
    • アジア太平洋：ヒト免疫不全ウイルス（HIV）治療薬市場、医薬品クラス別（2018年～2030年）
    • ヒト免疫不全ウイルス（HIV）治療薬市場-中国
    • ヒト免疫不全ウイルス（HIV）治療薬市場-インド
    • ヒト免疫不全ウイルス（HIV）治療薬市場-マレーシア
    • ヒト免疫不全ウイルス（HIV）治療薬市場-日本
    • ヒト免疫不全ウイルス（HIV）治療薬市場-インドネシア
    • ヒト免疫不全ウイルス（HIV）治療薬市場-韓国
  • ヒト免疫不全ウイルス（HIV）治療薬市場-中東およびアフリカ
    • 中東・アフリカ：ヒト免疫不全ウイルス（HIV）治療薬市場、流通チャネル別（2018年～2030年）
    • 中東・アフリカ：ヒト免疫不全ウイルス（HIV）治療薬市場、医薬品クラス別（2018年～2030年）
    • ヒト免疫不全ウイルス（HIV）治療薬市場-サウジアラビア
    • ヒト免疫不全ウイルス（HIV）治療薬市場-アラブ首長国連邦
    • ヒト免疫不全ウイルス（HIV）治療薬市場-イスラエル
    • ヒト免疫不全ウイルス（HIV）治療薬市場-南アフリカ
  • ヒト免疫不全ウイルス（HIV）治療薬市場-ラテンアメリカ
    • ラテンアメリカ：ヒト免疫不全ウイルス（HIV）治療薬市場、流通チャネル別（2018年～2030年）
    • ラテンアメリカ：ヒト免疫不全ウイルス（HIV）治療薬市場、医薬品クラス別（2018年～2030年）
    • ヒト免疫不全ウイルス（HIV）治療薬市場-メキシコ
    • ヒト免疫不全ウイルス（HIV）治療薬市場-ブラジル
    • ヒト免疫不全ウイルス（HIV）治療薬市場-アルゼンチン

第8章 競合情勢

  • 拡大・買収分析
    • 拡大
    • 買収
  • パートナーシップ/コラボレーション/契約/展示会

第9章 企業プロファイル

  • Boehringer Ingelheim
  • Cipla Limited
  • GlaxoSmithKline plc
  • Gilead Sciences, Inc.
  • Johnson & Johnson
  • Merck
  • Pfizer Inc.
  • Roche Ltd.
  • Teva Pharmaceutical Industries Ltd
図表

List of Tables

  • Table 1 Global Human Immunodeficiency Virus (HIV) Drugs Market, by Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 2 Global Human Immunodeficiency Virus (HIV) Drugs Market, by Drug Class, 2018 - 2030 (USD Billion)
  • Table 3 Human Immunodeficiency Virus (HIV) Drugs Market Assessment, By Geography, 2018 - 2030 (USD Billion)
  • Table 4 North America: Human Immunodeficiency Virus (HIV) Drugs Market, by Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 5 North America: Human Immunodeficiency Virus (HIV) Drugs Market, by Drug Class, 2018 - 2030 (USD Billion)
  • Table 6 U.S.: Human Immunodeficiency Virus (HIV) Drugs Market, by Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 7 U.S.: Human Immunodeficiency Virus (HIV) Drugs Market, by Drug Class, 2018 - 2030 (USD Billion)
  • Table 8 Canada: Human Immunodeficiency Virus (HIV) Drugs Market, by Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 9 Canada: Human Immunodeficiency Virus (HIV) Drugs Market, by Drug Class, 2018 - 2030 (USD Billion)
  • Table 10 Europe: Human Immunodeficiency Virus (HIV) Drugs Market, by Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 11 Europe: Human Immunodeficiency Virus (HIV) Drugs Market, by Drug Class, 2018 - 2030 (USD Billion)
  • Table 12 UK: Human Immunodeficiency Virus (HIV) Drugs Market, by Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 13 UK: Human Immunodeficiency Virus (HIV) Drugs Market, by Drug Class, 2018 - 2030 (USD Billion)
  • Table 14 France: Human Immunodeficiency Virus (HIV) Drugs Market, by Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 15 France: Human Immunodeficiency Virus (HIV) Drugs Market, by Drug Class, 2018 - 2030 (USD Billion)
  • Table 16 Germany: Human Immunodeficiency Virus (HIV) Drugs Market, by Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 17 Germany: Human Immunodeficiency Virus (HIV) Drugs Market, by Drug Class, 2018 - 2030 (USD Billion)
  • Table 18 Italy: Human Immunodeficiency Virus (HIV) Drugs Market, by Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 19 Italy: Human Immunodeficiency Virus (HIV) Drugs Market, by Drug Class, 2018 - 2030 (USD Billion)
  • Table 20 Spain: Human Immunodeficiency Virus (HIV) Drugs Market, by Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 21 Spain: Human Immunodeficiency Virus (HIV) Drugs Market, by Drug Class, 2018 - 2030 (USD Billion)
  • Table 22 Netherlands: Human Immunodeficiency Virus (HIV) Drugs Market, by Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 23 Netherlands: Human Immunodeficiency Virus (HIV) Drugs Market, by Drug Class, 2018 - 2030 (USD Billion)
  • Table 24 Russia: Human Immunodeficiency Virus (HIV) Drugs Market, by Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 25 Russia: Human Immunodeficiency Virus (HIV) Drugs Market, by Drug Class, 2018 - 2030 (USD Billion)
  • Table 26 Asia Pacific: Human Immunodeficiency Virus (HIV) Drugs Market, by Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 27 Asia Pacific: Human Immunodeficiency Virus (HIV) Drugs Market, by Drug Class, 2018 - 2030 (USD Billion)
  • Table 28 China: Human Immunodeficiency Virus (HIV) Drugs Market, by Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 29 China: Human Immunodeficiency Virus (HIV) Drugs Market, by Drug Class, 2018 - 2030 (USD Billion)
  • Table 30 India: Human Immunodeficiency Virus (HIV) Drugs Market, by Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 31 India: Human Immunodeficiency Virus (HIV) Drugs Market, by Drug Class, 2018 - 2030 (USD Billion)
  • Table 32 Malaysia: Human Immunodeficiency Virus (HIV) Drugs Market, by Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 33 Malaysia: Human Immunodeficiency Virus (HIV) Drugs Market, by Drug Class, 2018 - 2030 (USD Billion)
  • Table 34 Japan: Human Immunodeficiency Virus (HIV) Drugs Market, by Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 35 Japan: Human Immunodeficiency Virus (HIV) Drugs Market, by Drug Class, 2018 - 2030 (USD Billion)
  • Table 36 Indonesia: Human Immunodeficiency Virus (HIV) Drugs Market, by Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 37 Indonesia: Human Immunodeficiency Virus (HIV) Drugs Market, by Drug Class, 2018 - 2030 (USD Billion)
  • Table 38 South Korea: Human Immunodeficiency Virus (HIV) Drugs Market, by Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 39 South Korea: Human Immunodeficiency Virus (HIV) Drugs Market, by Drug Class, 2018 - 2030 (USD Billion)
  • Table 40 Middle East & Africa: Human Immunodeficiency Virus (HIV) Drugs Market, by Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 41 Middle East & Africa: Human Immunodeficiency Virus (HIV) Drugs Market, by Drug Class, 2018 - 2030 (USD Billion)
  • Table 42 Saudi Arabia: Human Immunodeficiency Virus (HIV) Drugs Market, by Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 43 Saudi Arabia: Human Immunodeficiency Virus (HIV) Drugs Market, by Drug Class, 2018 - 2030 (USD Billion)
  • Table 44 UAE: Human Immunodeficiency Virus (HIV) Drugs Market, by Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 45 UAE: Human Immunodeficiency Virus (HIV) Drugs Market, by Drug Class, 2018 - 2030 (USD Billion)
  • Table 46 Israel: Human Immunodeficiency Virus (HIV) Drugs Market, by Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 47 Israel: Human Immunodeficiency Virus (HIV) Drugs Market, by Drug Class, 2018 - 2030 (USD Billion)
  • Table 48 South Africa: Human Immunodeficiency Virus (HIV) Drugs Market, by Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 49 South Africa: Human Immunodeficiency Virus (HIV) Drugs Market, by Drug Class, 2018 - 2030 (USD Billion)
  • Table 50 Latin America: Human Immunodeficiency Virus (HIV) Drugs Market, by Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 51 Latin America: Human Immunodeficiency Virus (HIV) Drugs Market, by Drug Class, 2018 - 2030 (USD Billion)
  • Table 52 Mexico: Human Immunodeficiency Virus (HIV) Drugs Market, by Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 53 Mexico: Human Immunodeficiency Virus (HIV) Drugs Market, by Drug Class, 2018 - 2030 (USD Billion)
  • Table 54 Brazil: Human Immunodeficiency Virus (HIV) Drugs Market, by Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 55 Brazil: Human Immunodeficiency Virus (HIV) Drugs Market, by Drug Class, 2018 - 2030 (USD Billion)
  • Table 56 Argentina: Human Immunodeficiency Virus (HIV) Drugs Market, by Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 57 Argentina: Human Immunodeficiency Virus (HIV) Drugs Market, by Drug Class, 2018 - 2030 (USD Billion)

List of Figures

Figure 1 Global Human Immunodeficiency Virus (HIV) Drugs Market, 2018 - 2030 (USD Billion)

Figure 2 Integrated Ecosystem

Figure 3 Research Methodology: Top-Down & Bottom-Up Approach

Figure 4 Market by Geography

Figure 5 Porter's Five Forces

Figure 6 Market by Distribution Channel

Figure 7 Global Human Immunodeficiency Virus (HIV) Drugs Market, by Distribution Channel, 2021 & 2030 (USD Billion)

Figure 8 Market by Drug Class

Figure 9 Global Human Immunodeficiency Virus (HIV) Drugs Market, by Drug Class, 2021 & 2030 (USD Billion)

Figure 10 Human Immunodeficiency Virus (HIV) Drugs Market Assessment, By Geography, 2018 - 2030 (USD Billion)

Figure 11 Strategic Analysis - Human Immunodeficiency Virus (HIV) Drugs Market

目次
Product Code: PM1110

The global Human Immunodeficiency Virus (HIV) drugs market size is expected to reach USD 47.48 billion by 20230 according to a new study by Polaris Market Research. The report "Human Immunodeficiency Virus (HIV) Drugs Market Share, Size, Trends, Industry Analysis Report, By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others); By Drug Class; By Region; Segment Forecast, 2022 - 2030" gives a detailed insight into current market dynamics and provides analysis on future market growth.

Factors such as rising FDA approvals by the governments for HIV treatment across the globe are driving the industry growth during the forecast period. For instance, in December 2021, Apretude was licensed by the US Food and Drug Administration for pre-exposure prophylaxis (PrEP) in at-risk adults and youth weighing at least 35 kg to minimize the risk of sexually transmitted HIV. In January 2021, Cabenuva was approved by the US Food and Drug Administration for the diagnosis of human immunodeficiency virus type 1 (HIV-1) infectious disease in adults who are virologically suppressed on a secure antiretroviral treatment plan, have no history of therapeutic failure, and have no suspected or confirmed resistance towards either cabotegravir or rilpivirine.

Moreover, increased research activities will develop customized prospects for the industry to develop throughout the forecast period. Advancements in medical technology increase public and private sector attempt to raise awareness, and increased government financing will all contribute to the growth of the human immunodeficiency virus drugs industry. Other reasons, such as an increase in consumption of effective medicines and a rising acceptance rate for early genetic counseling, would have a positive impact on the growth rate of the industry. Furthermore, the rise of the industry will be fueled by increased disposable income, an increase in the number of occurrences of seizures, and a shift in lifestyle.

The hospital pharmacies segment accounted for the leading share in the industry. The category is expanding due to an increase in patient visits to hospitals for HIV drug treatment. In addition, rising sales of recommended antiretroviral medications for HIV therapy from hospital pharmacies would drive segmental growth.

Market players such as Roche Ltd., Boehringer Ingelheim, GlaxoSmithKline plc., Gilead Sciences, Inc., Johnson & Johnson, Merck, Pfizer Inc., Cipla Limited, and Teva Pharmaceutical Industries Ltd. are key players operating in the industry. In March 2021, Merck and Gilead signed a cooperation agreement to commercialize HIV therapy. This two-drug combination includes Gilead's "lenacapavir" and Merck's islatravir.

Polaris Market Research has segmented the Human Immunodeficiency Virus (HIV) drugs market report based on drug class, distribution channel, and region:

Human Immunodeficiency Virus (HIV) Drugs, Drug Class Outlook (Revenue - USD Billion, 2018 - 2030)

Nucleoside Reverse Transcriptase Inhibitors

Multi-Class Combination Products

Protease Inhibitors

HIV Integrase Strand Transfer Inhibitors

Non-Nucleoside Reverse Transcriptase Inhibitors

Entry Inhibitors - CCR5 Co-Receptor Antagonist

Fusion Inhibitors

Others

Human Immunodeficiency Virus (HIV) Drugs, Distribution Channel Outlook (Revenue - USD Billion, 2018 - 2030)

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Others

Human Immunodeficiency Virus (HIV) Drugs, Regional Outlook (Revenue - USD Billion, 2018 - 2030)

North America

U.S.

Canada

Europe

France

Germany

UK

Italy

Spain

Netherlands

Russia

Asia Pacific

China

India

Japan

Malaysia

South Korea

Indonesia

Latin America

Mexico

Brazil

Argentina

Middle East & Africa

UAE

Saudi Arabia

Israel

South Africa

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Human Immunodeficiency Virus (HIV) Drugs Market Insights

  • 4.1. Human Immunodeficiency Virus (HIV) Drugs Market - Industry Snapshot
  • 4.2. Human Immunodeficiency Virus (HIV) Drugs Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. A significant rise in number of HIV population worldwide
      • 4.2.1.2. Increasing R&D in the area of HIV infection
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. High cost
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTLE Analysis
  • 4.5. Human Immunodeficiency Virus (HIV) Drugs Industry trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Human Immunodeficiency Virus (HIV) Drugs Market, by Drug Class

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Human Immunodeficiency Virus (HIV) Drugs, by Drug Class, 2018 - 2030 (USD Billion)
  • 5.3. Nucleoside Reverse Transcriptase Inhibitors
    • 5.3.1. Global Human Immunodeficiency Virus (HIV) Drugs Market, by Nucleoside Reverse Transcriptase Inhibitors, by Region, 2018 - 2030 (USD Billion)
  • 5.4. Multi-Class Combination Products
    • 5.4.1. Global Human Immunodeficiency Virus (HIV) Drugs Market, by Multi-Class Combination Products, by Region, 2018 - 2030 (USD Billion)
  • 5.5. Protease Inhibitors
    • 5.5.1. Global Human Immunodeficiency Virus (HIV) Drugs Market, by Protease Inhibitors, by Region, 2018 - 2030 (USD Billion)
  • 5.6. HIV Integrase Strand Transfer Inhibitors
    • 5.6.1. Global Human Immunodeficiency Virus (HIV) Drugs Market, by HIV Integrase Strand Transfer Inhibitors, by Region, 2018 - 2030 (USD Billion)
  • 5.7. Non-Nucleoside Reverse Transcriptase Inhibitors
    • 5.7.1. Global Human Immunodeficiency Virus (HIV) Drugs Market, by Non-Nucleoside Reverse Transcriptase Inhibitors, by Region, 2018 - 2030 (USD Billion)
  • 5.8. Entry Inhibitors - CCR5 Co-Receptor Antagonist
    • 5.8.1. Global Human Immunodeficiency Virus (HIV) Drugs Market, by Entry Inhibitors - CCR5 Co-Receptor Antagonist, by Region, 2018 - 2030 (USD Billion)
  • 5.9. Fusion Inhibitors
    • 5.9.1. Global Human Immunodeficiency Virus (HIV) Drugs Market, by Fusion Inhibitors, by Region, 2018 - 2030 (USD Billion)
  • 5.10. Others
    • 5.10.1. Global Other Human Immunodeficiency Virus (HIV) Drugs Market, by Region, 2018 - 2030 (USD Billion)

6. Global Human Immunodeficiency Virus (HIV) Drugs Market, by Distribution Channel

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Human Immunodeficiency Virus (HIV) Drugs Market, by Distribution Channel, 2018 - 2030 (USD Billion)
  • 6.3. Hospital Pharmacies
    • 6.3.1. Global Human Immunodeficiency Virus (HIV) Drugs Market, by Hospital Pharmacies, by Region, 2018 - 2030 (USD Billion)
  • 6.4. Retail Pharmacies
    • 6.4.1. Global Human Immunodeficiency Virus (HIV) Drugs Market, by Retail Pharmacies, by Region, 2018 - 2030 (USD Billion)
  • 6.5. Online Pharmacies
    • 6.5.1. Global Human Immunodeficiency Virus (HIV) Drugs Market, by Online Pharmacies, by Region, 2018 - 2030 (USD Billion)
  • 6.6. Others
    • 6.6.1. Global Other Human Immunodeficiency Virus (HIV) Drugs Market, by Region, 2018 - 2030 (USD Billion)

7. Global Human Immunodeficiency Virus (HIV) Drugs Market, by Geography

  • 7.1. Key findings
  • 7.2. Introduction
    • 7.2.1. Human Immunodeficiency Virus (HIV) Drugs Market Assessment, By Geography, 2018 - 2030 (USD Billion)
  • 7.3. Human Immunodeficiency Virus (HIV) Drugs Market - North America
    • 7.3.1. North America: Human Immunodeficiency Virus (HIV) Drugs Market, by Distribution Channel, 2018 - 2030 (USD Billion)
    • 7.3.2. North America: Human Immunodeficiency Virus (HIV) Drugs Market, by Drug Class, 2018 - 2030 (USD Billion)
    • 7.3.3. Human Immunodeficiency Virus (HIV) Drugs Market - U.S.
      • 7.3.3.1. U.S.: Human Immunodeficiency Virus (HIV) Drugs Market, by Distribution Channel, 2018 - 2030 (USD Billion)
      • 7.3.3.2. U.S.: Human Immunodeficiency Virus (HIV) Drugs Market, by Drug Class, 2018 - 2030 (USD Billion)
    • 7.3.4. Human Immunodeficiency Virus (HIV) Drugs Market - Canada
      • 7.3.4.1. Canada: Human Immunodeficiency Virus (HIV) Drugs Market, by Distribution Channel, 2018 - 2030 (USD Billion)
      • 7.3.4.2. Canada: Human Immunodeficiency Virus (HIV) Drugs Market, by Drug Class, 2018 - 2030 (USD Billion)
  • 7.4. Human Immunodeficiency Virus (HIV) Drugs Market - Europe
    • 7.4.1. Europe: Human Immunodeficiency Virus (HIV) Drugs Market, by Distribution Channel, 2018 - 2030 (USD Billion)
    • 7.4.2. Europe: Human Immunodeficiency Virus (HIV) Drugs Market, by Drug Class, 2018 - 2030 (USD Billion)
    • 7.4.3. Human Immunodeficiency Virus (HIV) Drugs Market - UK
      • 7.4.3.1. UK: Human Immunodeficiency Virus (HIV) Drugs Market, by Distribution Channel, 2018 - 2030 (USD Billion)
      • 7.4.3.2. UK: Human Immunodeficiency Virus (HIV) Drugs Market, by Drug Class, 2018 - 2030 (USD Billion)
    • 7.4.4. Human Immunodeficiency Virus (HIV) Drugs Market - France
      • 7.4.4.1. France: Human Immunodeficiency Virus (HIV) Drugs Market, by Distribution Channel, 2018 - 2030 (USD Billion)
      • 7.4.4.2. France: Human Immunodeficiency Virus (HIV) Drugs Market, by Drug Class, 2018 - 2030 (USD Billion)
    • 7.4.5. Human Immunodeficiency Virus (HIV) Drugs Market - Germany
      • 7.4.5.1. Germany: Human Immunodeficiency Virus (HIV) Drugs Market, by Distribution Channel, 2018 - 2030 (USD Billion)
      • 7.4.5.2. Germany: Human Immunodeficiency Virus (HIV) Drugs Market, by Drug Class, 2018 - 2030 (USD Billion)
    • 7.4.6. Human Immunodeficiency Virus (HIV) Drugs Market - Italy
      • 7.4.6.1. Italy: Human Immunodeficiency Virus (HIV) Drugs Market, by Distribution Channel, 2018 - 2030 (USD Billion)
      • 7.4.6.2. Italy: Human Immunodeficiency Virus (HIV) Drugs Market, by Drug Class, 2018 - 2030 (USD Billion)
    • 7.4.7. Human Immunodeficiency Virus (HIV) Drugs Market - Spain
      • 7.4.7.1. Spain: Human Immunodeficiency Virus (HIV) Drugs Market, by Distribution Channel, 2018 - 2030 (USD Billion)
      • 7.4.7.2. Spain: Human Immunodeficiency Virus (HIV) Drugs Market, by Drug Class, 2018 - 2030 (USD Billion)
    • 7.4.8. Human Immunodeficiency Virus (HIV) Drugs Market - Netherlands
      • 7.4.8.1. Netherlands: Human Immunodeficiency Virus (HIV) Drugs Market, by Distribution Channel, 2018 - 2030 (USD Billion)
      • 7.4.8.2. Netherlands: Human Immunodeficiency Virus (HIV) Drugs Market, by Drug Class, 2018 - 2030 (USD Billion)
    • 7.4.9. Human Immunodeficiency Virus (HIV) Drugs Market - Russia
      • 7.4.9.1. Russia: Human Immunodeficiency Virus (HIV) Drugs Market, by Distribution Channel, 2018 - 2030 (USD Billion)
      • 7.4.9.2. Russia: Human Immunodeficiency Virus (HIV) Drugs Market, by Drug Class, 2018 - 2030 (USD Billion)
  • 7.5. Human Immunodeficiency Virus (HIV) Drugs Market - Asia Pacific
    • 7.5.1. Asia Pacific: Human Immunodeficiency Virus (HIV) Drugs Market, by Distribution Channel, 2018 - 2030 (USD Billion)
    • 7.5.2. Asia Pacific: Human Immunodeficiency Virus (HIV) Drugs Market, by Drug Class, 2018 - 2030 (USD Billion)
    • 7.5.3. Human Immunodeficiency Virus (HIV) Drugs Market - China
      • 7.5.3.1. China: Human Immunodeficiency Virus (HIV) Drugs Market, by Distribution Channel, 2018 - 2030 (USD Billion)
      • 7.5.3.2. China: Human Immunodeficiency Virus (HIV) Drugs Market, by Drug Class, 2018 - 2030 (USD Billion)
    • 7.5.4. Human Immunodeficiency Virus (HIV) Drugs Market - India
      • 7.5.4.1. India: Human Immunodeficiency Virus (HIV) Drugs Market, by Distribution Channel, 2018 - 2030 (USD Billion)
      • 7.5.4.2. India: Human Immunodeficiency Virus (HIV) Drugs Market, by Drug Class, 2018 - 2030 (USD Billion)
    • 7.5.5. Human Immunodeficiency Virus (HIV) Drugs Market - Malaysia
      • 7.5.5.1. Malaysia: Human Immunodeficiency Virus (HIV) Drugs Market, by Distribution Channel, 2018 - 2030 (USD Billion)
      • 7.5.5.2. Malaysia: Human Immunodeficiency Virus (HIV) Drugs Market, by Drug Class, 2018 - 2030 (USD Billion)
    • 7.5.6. Human Immunodeficiency Virus (HIV) Drugs Market - Japan
      • 7.5.6.1. Japan: Human Immunodeficiency Virus (HIV) Drugs Market, by Distribution Channel, 2018 - 2030 (USD Billion)
      • 7.5.6.2. Japan: Human Immunodeficiency Virus (HIV) Drugs Market, by Drug Class, 2018 - 2030 (USD Billion)
    • 7.5.7. Human Immunodeficiency Virus (HIV) Drugs Market - Indonesia
      • 7.5.7.1. Indonesia: Human Immunodeficiency Virus (HIV) Drugs Market, by Distribution Channel, 2018 - 2030 (USD Billion)
      • 7.5.7.2. Indonesia: Human Immunodeficiency Virus (HIV) Drugs Market, by Drug Class, 2018 - 2030 (USD Billion)
    • 7.5.8. Human Immunodeficiency Virus (HIV) Drugs Market - South Korea
      • 7.5.8.1. South Korea: Human Immunodeficiency Virus (HIV) Drugs Market, by Distribution Channel, 2018 - 2030 (USD Billion)
      • 7.5.8.2. South Korea: Human Immunodeficiency Virus (HIV) Drugs Market, by Drug Class, 2018 - 2030 (USD Billion)
  • 7.6. Human Immunodeficiency Virus (HIV) Drugs Market - Middle East & Africa
    • 7.6.1. Middle East & Africa: Human Immunodeficiency Virus (HIV) Drugs Market, by Distribution Channel, 2018 - 2030 (USD Billion)
    • 7.6.2. Middle East & Africa: Human Immunodeficiency Virus (HIV) Drugs Market, by Drug Class, 2018 - 2030 (USD Billion)
    • 7.6.3. Human Immunodeficiency Virus (HIV) Drugs Market - Saudi Arabia
      • 7.6.3.1. Saudi Arabia: Human Immunodeficiency Virus (HIV) Drugs Market, by Distribution Channel, 2018 - 2030 (USD Billion)
      • 7.6.3.2. Saudi Arabia: Human Immunodeficiency Virus (HIV) Drugs Market, by Drug Class, 2018 - 2030 (USD Billion)
    • 7.6.4. Human Immunodeficiency Virus (HIV) Drugs Market - UAE
      • 7.6.4.1. UAE: Human Immunodeficiency Virus (HIV) Drugs Market, by Distribution Channel, 2018 - 2030 (USD Billion)
      • 7.6.4.2. UAE: Human Immunodeficiency Virus (HIV) Drugs Market, by Drug Class, 2018 - 2030 (USD Billion)
    • 7.6.5. Human Immunodeficiency Virus (HIV) Drugs Market - Israel
      • 7.6.5.1. Israel: Human Immunodeficiency Virus (HIV) Drugs Market, by Distribution Channel, 2018 - 2030 (USD Billion)
      • 7.6.5.2. Israel: Human Immunodeficiency Virus (HIV) Drugs Market, by Drug Class, 2018 - 2030 (USD Billion)
    • 7.6.6. Human Immunodeficiency Virus (HIV) Drugs Market - South Africa
      • 7.6.6.1. South Africa: Human Immunodeficiency Virus (HIV) Drugs Market, by Distribution Channel, 2018 - 2030 (USD Billion)
      • 7.6.6.2. South Africa: Human Immunodeficiency Virus (HIV) Drugs Market, by Drug Class, 2018 - 2030 (USD Billion)
  • 7.7. Human Immunodeficiency Virus (HIV) Drugs Market - Latin America
    • 7.7.1. Latin America: Human Immunodeficiency Virus (HIV) Drugs Market, by Distribution Channel, 2018 - 2030 (USD Billion)
    • 7.7.2. Latin America: Human Immunodeficiency Virus (HIV) Drugs Market, by Drug Class, 2018 - 2030 (USD Billion)
    • 7.7.3. Human Immunodeficiency Virus (HIV) Drugs Market - Mexico
      • 7.7.3.1. Mexico: Human Immunodeficiency Virus (HIV) Drugs Market, by Distribution Channel, 2018 - 2030 (USD Billion)
      • 7.7.3.2. Mexico: Human Immunodeficiency Virus (HIV) Drugs Market, by Drug Class, 2018 - 2030 (USD Billion)
    • 7.7.4. Human Immunodeficiency Virus (HIV) Drugs Market - Brazil
      • 7.7.4.1. Brazil: Human Immunodeficiency Virus (HIV) Drugs Market, by Distribution Channel, 2018 - 2030 (USD Billion)
      • 7.7.4.2. Brazil: Human Immunodeficiency Virus (HIV) Drugs Market, by Drug Class, 2018 - 2030 (USD Billion)
    • 7.7.5. Human Immunodeficiency Virus (HIV) Drugs Market - Argentina
      • 7.7.5.1. Argentina: Human Immunodeficiency Virus (HIV) Drugs Market, by Distribution Channel, 2018 - 2030 (USD Billion)
      • 7.7.5.2. Argentina: Human Immunodeficiency Virus (HIV) Drugs Market, by Drug Class, 2018 - 2030 (USD Billion)

8. Competitive Landscape

  • 8.1. Expansion and Acquisition Analysis
    • 8.1.1. Expansion
    • 8.1.2. Acquisitions
  • 8.2. Partnerships/Collaborations/Agreements/Exhibitions

9. Company Profiles

  • 9.1. Boehringer Ingelheim
    • 9.1.1. Company Overview
    • 9.1.2. Financial Performance
    • 9.1.3. Product Benchmarking
    • 9.1.4. Recent Development
  • 9.2. Cipla Limited
    • 9.2.1. Company Overview
    • 9.2.2. Financial Performance
    • 9.2.3. Product Benchmarking
    • 9.2.4. Recent Development
  • 9.3. GlaxoSmithKline plc
    • 9.3.1. Company Overview
    • 9.3.2. Financial Performance
    • 9.3.3. Product Benchmarking
    • 9.3.4. Recent Development
  • 9.4. Gilead Sciences, Inc.
    • 9.4.1. Company Overview
    • 9.4.2. Financial Performance
    • 9.4.3. Product Benchmarking
    • 9.4.4. Recent Development
  • 9.5. Johnson & Johnson
    • 9.5.1. Company Overview
    • 9.5.2. Financial Performance
    • 9.5.3. Product Benchmarking
    • 9.5.4. Recent Development
  • 9.6. Merck
    • 9.6.1. Company Overview
    • 9.6.2. Financial Performance
    • 9.6.3. Product Benchmarking
    • 9.6.4. Recent Development
  • 9.7. Pfizer Inc.
    • 9.7.1. Company Overview
    • 9.7.2. Financial Performance
    • 9.7.3. Product Benchmarking
    • 9.7.4. Recent Development
  • 9.8. Roche Ltd.
    • 9.8.1. Company Overview
    • 9.8.2. Financial Performance
    • 9.8.3. Product Benchmarking
    • 9.8.4. Recent Development
  • 9.9. Teva Pharmaceutical Industries Ltd
    • 9.9.1. Company Overview
    • 9.9.2. Financial Performance
    • 9.9.3. Product Benchmarking
    • 9.9.4. Recent Development